We, Aprogen, Inc., are a listed company on the Korea Exchange (007460:KS) with over 20 years of experience in biological R&D and are one of Korea’s foremost biopharmaceutical companies with over 200 R&D and 350 GMP staff. We have developed multiple and distinctive antibody and receptor engineering technologies that empower novel drug discovery and development. We have also accumulated various knowledge in proprietary cell line development and cell culturing methods that allow us to achieve exceptional productivity of up to 30 times the industry average. Utilizing these technological innovations, we currently have 7 Biosimilars and 5 Novel Drugs in our pipeline, where all of 12 are waiting for partners to maximize their respective potentials. We also have an in-house state-of-the-art manufacturing facility that can internalize manufacturing from cell culture to packaging that allows superior cost competitiveness and efficiency with lower CAPEX with land available for further expansion.